LY3154207

DRUG6 trials

Sponsors

Eli Lilly and Company

Conditions

HealthyHealthy ParticipantsLewy Body DementiaParkinson's Disease

Phase 1

A Study of LY3154207 in Healthy Participants

CompletedNCT02365571

Eli Lilly and CompanyHealthy Participants

Start: 2015-02-28End: 2015-05-31Updated: 2015-06-11

A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease

CompletedNCT02562768

Eli Lilly and CompanyParkinson's Disease

Start: 2015-09-30End: 2017-03-03Updated: 2017-03-21

A Study of LY3154207 on Sleep in Healthy Male Participants

CompletedNCT02603861

Eli Lilly and CompanyHealthy

Start: 2015-11-30End: 2016-03-31Updated: 2016-04-06

Study of LY3154207 in Healthy Participants

CompletedNCT03616795

Eli Lilly and CompanyHealthy

Start: 2018-08-09End: 2018-11-05Updated: 2018-11-26

A Study to Evaluate LY3154207 on the Brain of Healthy Participants

CompletedNCT04258826

Eli Lilly and CompanyHealthy

Start: 2021-01-15End: 2022-01-28Updated: 2022-02-22

Phase 2

A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)

CompletedNCT03305809

Eli Lilly and CompanyLewy Body Dementia

Start: 2017-11-09End: 2020-07-10Updated: 2021-07-23

Related Papers

Wrist-worn sensor-based measurements for drug effect detection with small samples in people with Lewy Body Dementia

Parkinsonism & Related Disorders2023-03-0313 citations

Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects

Clinical Pharmacology in Drug Development2020-10-0723 citations

P1‐057: A MULTIPLE ASCENDING‐DOSE STUDY OF THE PHARMACOKINETICS AND SAFETY OF LY3154207, A CENTRALLY‐ACTING DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR (D1 PAM), IN HEALTHY SUBJECTS

Alzheimer s & Dementia2019-07-01